Impact of Combining Meropenem and Ulinastatin on Inflammatory Responses and Complications in Severe Septic Shock Patients
By
Dan Wu
Wei Ni
Xinying Zhang
Xiaodong Liu
July 21, 2026
Clinical Scorecard: Impact of Combining Meropenem and Ulinastatin on Inflammatory Responses and Complications in Severe Septic Shock Patients
At a Glance
Category Detail
Condition Severe Septic Shock Key Mechanisms Inflammatory response modulation, coagulation stabilization, and tissue perfusion improvement. Target Population Patients with severe septic shock. Care Setting Single-center retrospective cohort study.
Key Highlights
Observation group showed higher overall response rate (90.6%) compared to control (73.6%). Lower levels of inflammatory markers (CRP, PCT, IL-6, IL-8, TNF-α) in the observation group. Improved hemodynamic parameters (HR, MAP, CI) in the observation group. Shorter ICU stay and mechanical ventilation duration in the observation group. Lower complication rate in the observation group (9.4%) compared to control (24.5%). Guideline-Based Recommendations
Diagnosis
Septic shock is defined by sustained hypotension unresponsive to fluid resuscitation. Management
Initiate broad-spectrum antibiotics, such as carbapenems, within the first hour after septic shock identification. Monitoring & Follow-up
Monitor inflammatory markers, coagulation parameters, and lactate clearance rates. Risks
High morbidity and mortality associated with severe septic shock. Patient & Prescribing Data
106 patients with severe septic shock.
Combination of meropenem and ulinastatin may improve inflammatory and clinical outcomes.
Clinical Best Practices
Use of ulinastatin as an adjunct to meropenem in severe septic shock may enhance patient outcomes. Regular assessment of inflammatory and coagulation markers is essential in managing septic shock. Related Resources & Content
